Most people at a plateau make the same mistake: they try harder at whatever stopped working. More restriction, more cardio, same approach. A plateau usually signals a metabolic shift, not a willpower problem, and that distinction matters when you’re picking a program to break through it.
The providers below range from bare-bones compounding scripts to full-team obesity medicine practices. Prices are cash-pay unless noted.
1. HealthRX
Compounded semaglutide starts at $99/month, compounded tirzepatide at $149. For cash-pay GLP-1 telehealth, those are genuinely low entry points, not promotional rates attached to a long contract. The medication ships overnight from Manifest Pharmacy in Greer, South Carolina, a 503A/USP-797-certified compounding pharmacy with lot-level tracking. A board-certified physician reviews your intake assessment within roughly 24 hours. Free overnight shipping covers all 50 states, and LegitScript certification (cert 50087439) adds a layer of external verification that many similar services skip entirely. Compounded medications are not FDA-approved, and HealthRX does not claim equivalency to any branded drug.
Verdict: Best overall value for cash-pay GLP-1 access, with a named pharmacy and transparent pricing from the start.
2. FormBlends
FormBlends runs a compounded GLP-1 telehealth service with physician oversight and dispenses through an FDA-registered 503A compounding pharmacy. The differentiator is published purity documentation: HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results are listed per product, not just referenced in general terms. Semaglutide runs around $299 per vial, tirzepatide around $349, putting it above HealthRX on price. Coverage reaches 47 states. Beyond GLP-1s, it carries a broader peptide catalog covering recovery, longevity, and cognitive categories, all under the same clinician model. Most GLP-1-only telehealth brands don’t offer that combination.
Verdict: Strong pick if published lab testing matters to you, or if you want GLP-1s and additional peptide protocols from one provider. Higher cost than HealthRX.
3. Mochi Health
Mochi uses board-certified obesity medicine clinicians, which is a meaningful distinction. Most telehealth platforms route prescriptions through general practitioners or NPs. Compounded semaglutide is around $99/month, tirzepatide around $199. The monitoring is more hands-on than the average script-and-ship model, which matters at a plateau when dose adjustments and accountability actually move the needle.
Verdict: Good middle ground between price and clinical depth.
4. Hims & Hers
After the March 2026 Novo Nordisk settlement, Hims & Hers moved away from compounded GLP-1s to branded medications. Injectable Wegovy runs approximately $299/month through the platform, oral options around $249, and Zepbound around $399. With insurance and a manufacturer savings card, some users land in the $0 to $25 range. Biggest name in consumer telehealth. Also the most expensive at full cash price.
Verdict: Reasonable if you have insurance or savings card access; expensive if you’re paying cash.
5. Ro Body
Ro’s first month runs about $39, then $74 to $149 monthly, with medications billed separately. The platform has a dedicated prior-authorization team and accepts insurance for branded medications. That prior-auth support is genuinely useful when you’re fighting for Wegovy or Zepbound coverage and your insurer keeps pushing back.
Verdict: Worth it specifically if insurance is in the picture and you need someone to manage the authorization process.
6. Form Health
Premium tier. Around $299/month, which includes labs, medication, MD oversight, and a registered dietitian. The MD-plus-dietitian pairing is unusual in telehealth and directly relevant to plateaus, since dietitians can recalibrate your actual intake in ways that a medication adjustment alone can’t.
Verdict: Expensive but the most clinically thorough option on this list.
7. Found
Found charges approximately $99/month for the platform, with medication costs on top. It includes coaching alongside the prescription side, which gives it more structure than a simple prescribing service. Not as deep as Form Health’s clinical model, but more support than most.
Verdict: Decent midrange option if you want coaching without a premium price.
8. Henry Meds
Cash-pay compounding, first-month pricing around $179 to $249, with shipping in 24 to 72 hours. Lighter monitoring than Mochi or Form Health. Good for someone who knows what they want and doesn’t need intensive check-ins.
Verdict: Fast and straightforward. Less hand-holding, which suits some people fine.
9. PlushCare
PlushCare membership runs about $19.99/month, with branded medications billed separately. Same-day appointments are available. It accepts insurance and works with branded GLP-1s rather than compounded options, which matters post-2026 as the regulatory environment around compounding has tightened significantly.
Verdict: Low barrier to entry, insurance-friendly, branded meds only.
10. Calibrate
Calibrate structures its program over roughly 12 months, with a separate program fee and medication costs. The longer commitment is intentional: the program treats the plateau as a metabolic problem requiring sustained behavioral change, not just a prescription. Heavier coaching than most. Also a bigger time and financial commitment.
Verdict: For people who want structure over a full year and aren’t looking for the cheapest monthly option.
A Quick Note on Compounded GLP-1s
The FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026. Compounded medications are not FDA-approved. Any provider on this list offering compounded semaglutide or tirzepatide should be evaluated on pharmacy credentials, not just price.
Common Questions
Does switching programs actually help when GLP-1 medication alone stopped producing results?
Sometimes, yes. Medication alone rarely solves a plateau that has lasted more than a few weeks. Programs that pair dose adjustment with dietitian input, like Form Health, or structured behavioral coaching, like Calibrate, address the intake and adaptation side that a prescription change by itself tends to miss entirely.
Which of these programs will work with my insurance to cover Wegovy or Zepbound?
Ro Body has a dedicated prior-authorization team built specifically for that fight, making it the strongest option if insurer pushback is your main obstacle. PlushCare also accepts insurance and prescribes branded medications only. Hims & Hers works with manufacturer savings cards, which can bring Wegovy costs down to $0 to $25 per month for eligible patients.
How do HealthRX and FormBlends differ on pharmacy transparency, and why does that matter for a plateau patient reconsidering their compounded GLP-1?
HealthRX names its pharmacy outright: Manifest Pharmacy in Greer, South Carolina, a 503A/USP-797-certified facility with lot-level tracking. FormBlends publishes per-product lab results including HPLC purity percentages and endotoxin data. Both approaches give you something to verify. Generic claims of “quality compounding” with no supporting documentation give you nothing.
Is a 12-month program like Calibrate overkill if I just need to break a short plateau?
Probably, yes. Calibrate is designed for sustained metabolic change over a full year, with coaching to match. If your plateau is recent and you mainly need a medication or dose recalibration, a lighter platform like Mochi Health or HealthRX is a more proportionate starting point. Calibrate makes more sense when previous shorter programs haven’t held.
What changed after the March 2026 Novo Nordisk settlement, and how does it affect which program you can choose?
The settlement pushed platforms like Hims & Hers away from compounded semaglutide toward branded medications, which cost significantly more at cash pay. Simultaneously, FDA warning letters to more than 30 compounding firms tightened the field. Programs still offering compounded options, like HealthRX, FormBlends, Mochi, and Henry Meds, should be vetted on pharmacy credentials before price becomes the deciding factor.
Sources
- FDA: Compounded Drug Products FAQs and 2026 warning letter announcements (FDA.gov)
- SURMOUNT-1 trial: tirzepatide efficacy data, published in *New England Journal of Medicine*, 2022
- STEP 1 trial: semaglutide efficacy data, published in *New England Journal of Medicine*, 2021
- Coverage of the Novo Nordisk legal settlement reached in March 2026 (Reuters, STAT News)
- LegitScript certification database (LegitScript.com)
